References

9/15/03 Cancer

References
9/15/03 Cancer

1. White JD. The National Cancer Institutes perspective and agenda for promoting awareness and research on alternative therapies for cancer. J Altern Complement Med. 8, 5:545-50, 2002. www.liebertpub.com.

2. Seifried HE et al. The antioxidant conundrum in cancer. Cancer Res. 63, 15:4295-8, 2003. http://cancerres.aacrjournals.org.

3. Taking vitamin supplements to prevent cardiovascular disease and cancer: recommendations form the U.S. Preventive Services Task Force. Ann Int Med. 139, 1:1-76, 2003. www.annals.org.

4. Jacobs EJ et al. Vitamin C and vitamin E supplement use and bladder cancer mortality in a large cohort of U.S. men and women. Am J Epidemiol. 156, 11:1002-10, 2002. www.aje.oupjournals.org.

5. Virtamo J et al. Incidence of cancer and mortality following alpha-tocopherol and beta-carotene supplementation: Postintervention follow-up. JAMA. 290, 4:476-85, 2003. www.jama.com.

6. Prasad KN et al. Alpha-tocopheryl succinate, the most effective form of vitamin E for adjuvant cancer treatment: a review. J Am Coll Nutr. 22, 2:108-17, 2003. www.jacn.org.

7. Huang HY et al. Prospective study of antioxidant micronutrients in the blood and the risk of developing prostate cancer. Am J Epidemiol. 175, 4:335-44, 2003. www.aje.oupjournals.org.

8. Guthrie N et al. Inhibition of proliferation of estrogen receptor-negative MDA-MB-435 and -positive MCF-7 human breast cancer cells by palm oil tocotrienols and tamoxifen, alone and in combination. J Nutr. 127, 3:544S-548S, 1997. www.nutrition.org.

9. Nesaretnam K et al. Tocotrienols inhibit the growth of human breast cancer cells irrespective of estrogen receptor status. Lipids. 33, 5:461-9, 1998. www.aocs.org.

10. Nesaretnam K et al. Tocotrienols inhibit growth of ZR-75-1 breast cancer cells. Int J Food Sci Nutr. 51, Suppl:S95-103, 2000. www.medbioworld.com/bio/journals/food.html.

11. Simon JA et al. Relation of serum ascorbic acid to Helicobacter pylori serology in US adults: the Third National Health and Nutrition Examination Survey. J Am Coll Nutr. 22, 4:283-9, 2003. www.jacn.org.

12. Sandoval M et al. Antioxidant and biological properties of Myrciaria dubia: Role in Cytoprotection. Oxygen. 2001.

13.Justi KC et al. Nutritional composition and vitamin C stability in stored camu-camu (Myrciaria dubia) pulp. Arch Latinoam Nutr. 50, 4:405-8, 2000.

14. Satia-About a J et al. Associations of micronutrients with colon cancer risk in African Americans and whites: results from the North Carolina colon cancer study. Cancer Epidemiol Biomarkers Prev. 12, 8:747-54, 2003. http://cebp.aacrjournals.org.

15. Pradeep CR, Kuttan G. Effect of beta-carotene on the inhibition of lung metastasis in mice. Phytomedicine. 10, 2-3:159-64, 2003. www.urbanfischer.de/journals/frame_template.htm?/journals/phytomed/phytmed.htm.

16. Paolini M et al. Beta-carotene: a cancer chemopreventive agent or a co-carcinogen? Mutat Res. 543, 3:195-200, 2003. www.mutationresearch.com.

17. Baron JA et al. Neoplastic and antineoplastic effects of beta-carotene on colorectal adenoma recurrence: results of a randomized trial. J Natl Cancer Inst. 95, 10:717-22, 2003. http://jncicancerspectrum.oupjournals.org/jnci.

18. Palozza P et al. Beta-carotene regulates NF-kappaB DNA-binding activity by a redox mechanism in human leukemia and colon adenocarcinoma cells. J Nutr. 133, 2:381-8, 2003. www.nutrition.org.

19. Muhlhofer A et al. Carotenoids are decreased in biopsies from colorectal adenomas. Clin Nutr. 22, 1:65-70, 2003. www.harcourt-international.com/journals/clnu.

20. Pohar KS et al. Tomatoes, lycopene and prostate cancer: a clinicians guide for counseling those at risk for prostate cancer. World J Urol. 21, 1:9-14, 2003. http://link.springer.de/link/service/journals/00345.

21. Bowen P et al. Tomato sauce supplementation and prostate cancer: lycopene accumulation and modulation of biomarkers of carcinogenesis. Exp Biol Med (Maywood). 227, 10:886-93, 2002. www.ebmonline.org.

22. Kim L et al. Effect of lycopene on prostate LNCaP cancer cells in culture. J Med Food. 5, 4:181-7, 2002. www.liebertpub.com.

23. Kucuk O et al. Effects of lycopene supplementation in patients with localized prostate cancer. Exp Biol Med (Maywood). 227, 10:881-5, 2002. www.ebmonline.org.

24. Miller EC et al. Tomato products, lycopene, and prostate cancer risk. Urol Clin North Am. 29, 1:83-93, 2002. http://info.med.yale.edu/library/sir/openjournals/clinicsna.html.

25. Li Z et al. [The effects of carotenoids on the proliferation of human breast cancer cell and gene expression of bcl-2.] (Article in Chinese.) Zhonghua Yu Fang Yi Xue Za Zhi. 36, 4:254-7, 2002.

26. Sato R et al. Prospective study of carotenoids, tocopherols and retinoid concentrations and the risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 11, 5:451-7, 2002. http://cebp.aacrjournals.org.

27. Hulten K et al. Carotenoids, alpha-tocopherols, and retinol in plasma and breast cancer risk in Northern Sweden. Cancer Causes Control. 12, 6:529-37, 2001. www.kluweronline.com/issn/0957-5243/contents.

28. Kim DJ et al. Chemoprevention of lung cancer by lycopene. Biofactors. 13, 1-4:95-102, 2000. www.iospress.nl/site/html/09516433.html.

29. Nishino H et al. American Academy of Cancer Research.

30. Kurihara H et al. Contribution of the antioxidative property of astaxanthin to its protective effect on the promotion of cancer metastasis in mice treated with restraint stress. Life Sci. 70, 21:2509-20, 2002. www.sciencedirect.com/science/journal/00243205.

31. Jyonouchi H et al. Antitumor activity of astaxanthin and its mode of action. Nutr Cancer. 36, 1:59-65, 2000. www.erlbaum.com/Journals/journals/NC/nc.htm.

32. Hodges S et al. CoQ10: Could it have a role in cancer management? Biofactors. 9, 2-4:365-70, 1999. www.iospress.nl/site/html/09516433.html.

33. Leitzmann MF et al. Zinc supplement use and risk of prostate cancer. J Natl Cancer Inst. 95, 13:1004-7, 2003. http://jncicancerspectrum.oupjournals.org/jnci.

34. Hadden JW. Immunodeficiency and cancer: prospects for correction. Int Immunopharmacol. 3, 8:1061-71, 2003. www.elsevier.com/locate/intimp.

35. Yousef MI et al. "Dietary zinc deficiency induced-changes in the activity of enzymes and the levels of free radicals, lipids and protein electrophoretic behavior in growing rats." Toxicology. 175, 1-3:223-34, 2002. www.elsevier.com/inca/publications/store/5/0/5/5/1/8.

36. Zeegers MP et al. Prediagnostic toenail selenium and risk of bladder cancer. Cancer Epidemiol Biomarkers Prev. 11, 11:1292-7, 2002. http://cebp.aacrjournals.org.

37. Hartman TJ et al. Toenail selenium concentration and lung cancer in male smokers (Finland). Cancer Causes Control. 13, 10:923-8, 2002. www.kluweronline.com/issn/0957-5243/contents.

38. Waters DJ et al. Effects of dietary selenium supplementation on DNA damage and apoptosis in canine prostate. J Natl Cancer Inst. 95, 3:237-41, 2003. http://jncicancerspectrum.oupjournals.org/jnci.

39. Duffield-Lillico AJ et al. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int. 91, 7:608-12, 2003.

40. Komatsu S et al. Antitumor effect of vitamin B6 and its mechanisms. Biochim Biophys Acta. 1647, 1-2:127-30, 2003.

41. Matsubara K et al. Vitamin B6-mediated suppression of colon tumorigenesis, cell proliferation, and angiogenesis (review). J Nutr Biochem. 14, 5:246-50, 2003. www.elsevier.com/locate/jnutbio.

42. Zhang SM et al. Plasma folate, vitamin B6, vitamin B12, homocysteine and risk of breast cancer. J Natl Cancer Inst. 95, 5:373-80, 2003. http://jncicancerspectrum.oupjournals.org/jnci.

43. Zhu S et al. The effect of folic acid on the development of stomach and other gastrointestinal cancers. Chin Med J (Engl). 116, 1:15-9, 2003.

44. Khosraviani K et al. Effect of folate supplementation on mucosal cell proliferation in high risk patients for colon cancer. Gut. 51:195-9, 2002. http://gut.bmjjournals.com.

45. Pufulete M et al. Folate status, genomic DNA hypomethylation, and risk of colorectal adenoma and cancer: a case control study. Gastroenterology. 124, 5:1240-8, 2003. www.gastrojournal.org.

46. Raval GN et al. Vitamin B(12) and folate status in head and neck cancer. Asian Pac J Cancer Prev. 3, 2:155-62, 2002.

47. Lamprecht SA, Lipkin M. Chemoprevention of colon cancer by calcium, vitamin D and folate: molecular mechanisms. Nat Rev Cancer. 3, 8:601-14, 2003. www.nature.com/nrc.

48. Rodriguez C et al. Calcium, dairy products, and risk of prostate cancer in a prospective cohort of United States men. Cancer Epidemiol Biomarkers Prev. 12, 7:597-603, 2003. http://cebp.aacrjournals.org.

49. Guyton KZ et al. Vitamin D and vitamin D analogs as cancer chemopreventive agents. Nutr Rev. 61, 7:227-38, 2003. www.ilsi.org/publications/reviews.html.

50. Chen TC et al. Evaluation of vitamin D analogs as therapeutic agents for prostate cancer. Recent Results Cancer Res. 164:273-88, 2003. www.springer.de/medic/fglisten/oncology/series.html.

51. OKelly J, Koeffler HP. Vitamin D analogs and breast cancer. Recent Results Cancer Res. 164:333-48, 2003. www.springer.de/medic/fglisten/oncology/series.html.

52. Friedrich M et al. Analysis of the vitamin D system in cervical carcinomas, breast cancer and ovarian cancer. Recent Results Cancer Res. 164:239-46, 2003. www.springer.de/medic/fglisten/oncology/series.html.

53. Su SJ et al. Effects of soy isoflavones on apoptosis induction and G2-M arrest in human hepatoma cells involvement of caspase-3 activation, Bcl-2 and Bcl-XL downregulation, and Cdc2 kinase activity. Nutr Cancer. 45, 1:113-23, 2003. www.erlbaum.com/Journals/journals/NC/nc.htm.

54. Gentile MS et al. Targeting colon cancer cells with genistein-17.1A immunoconjugate. Int J Oncol. 22, 5:955-9, 2003. www.erlbaum.com/Journals/journals/NC/nc.htm.

55. Toyomura K, Kono S. Soybeans, soy foods, isoflavones and risk of colorectal cancer: a review of experimental and epidemiological data. Asian Pac J Cancer Prev. 3, 2:125-32, 2002.

56. Messina MJ. Emerging evidence on the role of soy in reducing prostate cancer risk. Nutr Rev. 61, 4:117-31, 2003. www.ilsi.org/publications/reviews.html.

57. Lee MM et al. Soy and isoflavone consumption in relation to prostate cancer risk in China. Cancer Epidemiol Biomarkers Prev. 12, 7:665-8, 2003. http://cebp.aacrjournals.org.

58. Pollard M, Wolter W. Prevention of spontaneous prostate-related cancer in Lobund-Wistar rats by a soy protein isolate/isoflavone diet. Prostate. 45, 2:101-5, 2000. www.wileyeurope.com/WileyCDA/WileyTitle/productCd-PROS.html.

59. Bylund A et al. Rye bran and soy protein delay growth and increase apoptosis of human LNCaP prostate adenocarcinoma in nude mice. Prostate. 42, 4:304-14, 2000. www.wileyeurope.com/WileyCDA/WileyTitle/productCd-PROS.html.

60. deVere White R et al. Annual Meeting of the American Urological Association, Chicago, April 26-May 1, 2003. www.auanet.org.

61. Ghafar MA et al. Regression of prostate cancer following administration of genistein combined polysaccharide (GCP), a nutritional supplement: case report. J Altern Comp Med. 8, 4:493-7, 2003. www.liebertpub.com.

62. Yu Z et al. [Genistein induced apoptosis in MCF-7 and T47D cells.] (Article in Chinese.) Wei Sheng Yan Jiu. 32, 2:125-7, 2003.

63. Chen WF et al. Inhibitory actions of genistein in human breast cancer (MCF-7) cells. Biochim Biophys Acta. 1638, 2:17-96, 2003. www.elsevier.nl/locate/bba.

64. Hewitt AL et al. Soy extract inhibits mammary adenocarcinoma growth in a syngeneic mouse model. Cancer Lett. 192, 2:133-43, 2003. www.elsevier.com/locate/canlet.

65. Yamamoto S et al. Soy, isoflavones, and breast cancer risk in Japan. J Natl Cancer Inst. 95, 12:906-13, 2003. http://jncicancerspectrum.oupjournals.org/jnci.

66. Kurzer MS. Phytoestrogen supplement use by women. J Nutr. 133, 6:1983S-1986S, 2003. www.nutrition.org.

67. Ju YH et al. Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice. Cancer Res. 62, 9:2474-77, 2002. http://cancerres.aacrjournals.org.

68. Jarred RA et al. Induction of apoptosis in low to moderate-grade human prostate carcinoma by red clover-derived dietary isoflavones. Cancer Epidemiol Biomarkers Prev. 11, 12:1689-96, 2002. http://cebp.aacrjournals.org.

69. Wu AH et al. Green tea and risk of breast cancer in Asian Americans. Int J Cancer. 106, 4:574-9, 2003. www3.interscience.wiley.com.

70. Demeule M et al. Green tea catechins as novel antitumor and antiangiogenic compounds. Curr Med Chem Anti-Canc Agents. 2, 4:441-63, 2002.

71. Kemberling JK et al. Inhibition of bladder tumor growth by the green tea derivative epigallocatechin-3-gallate. J Urol. 170, 3:773-6, 2003. www.jurology.com.

72. Ahn WS et al. A major constituent of green tea, EGCG, inhibits the growth of a human cervical cancer cell line, CaSki cells, through apoptosis, G(1) arrest, and regulation of gene expression. DNA Cell Biol. 22, 3:217-24, 2003.

73. Palermo CM et al. Identification of potential aryl hydrocarbon receptor antagonists in green tea. Chem Res Toxicol. 16, 7:865-72, 2003.

74. Roy M et al. Anticlastogenic, antigenotoxic and apoptotic activity of epigallocatechin gallate: a green tea polyphenol. Mutat Res. 523-524:33-41, 2003. www.mutationresearch.com.

75. Chung JH et al. Dual mechanisms of green tea extract-induced cell survival in human epidermal keratinocytes. FASEB J, Aug. 1, 2003, Epub ahead of print. www.fasebj.org.

76. Katiyar SK. Skin photoprotection by green tea: antioxidant and immunomodulatory effects. Curr Drug Targets Immune Endocr Metabol Disord. 3, 3:234-42, 2003.

77. Linden KG et al. Chemoprevention of nonmelanoma skin cancer: experience with a polyphenol from green tea. Recent Results Cancer Res. 163:165-72, 2003. www.springer.de/medic/fglisten/oncology/series.html.

78. Mu LN et al. [A case-control study on drinking green tea and decreasing risk of cancers in the alimentary canal among cigarette smokers and alcohol drinkers.] Zhonghua Liu Xing Bing Xue Za Zhi. 24, 3:192-5, 2003.

79. Jatoi A et al. A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer. 97, 6:1442-6, 2003. www.interscience.wiley.com/jpages/0008-543X.

80. Singletary KW, Meline B. Effect of grape seed proanthocyanidins on colon aberrant crypts and breast tumors in a rat dual-organ tumor model. Nutr Cancer. 39, 2:252-8, 2001. www.erlbaum.com/Journals/journals/NC/nc.htm.

81. Bagchi D et al. Cellular protection with proanthocyanidins derived from grape seeds. Ann N Y Acad Sci. 957:260-70, 2002. www.nyas.org/publications/annals.

82. Joshi SS et al. Amelioration of the cytotoxic effects of chemotherapeutic agents by grape seed proanthocyanidin extract. Antioxid Redox Signal. 1, 4:563-70, 1999.

83. Thomson M, Ali M. Garlic [Allium sativum]: a review of its potential use as an anti-cancer agent. Curr Cancer Drug Targets. 3, 1:67-81, 2003.

84. Hsing AW et al. Allium vegetables and risk of prostate cancer: a population-based study. J Natl Cancer Inst. 94, 21:1648-51, 2002. http://jncicancerspectrum.oupjournals.org/jnci.

85. Durak I et al. Consumption of aqueous garlic extract leads to significant improvement in patients with benign prostate hyperplasia and prostate cancer. Nutr Res. 23, 2:199-204, 2003. www.elsevier.com/locate/issn/02715317.

86. Marks LS et al. Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. J Urol. 163, 5:1451-6, 2000. www.jurology.com

87. Gerber GS. Saw palmetto for the treatment of men with lower urinary tract symptoms. J Urol. 163, 5:1408-12, 2000. www.jurology.com

88. Goldmann WH et al. Saw palmetto berry extract inhibits cell growth and Cox-2 expression in prostatic cancer cells. Cell Biol Int. 25, 11:1117-24, 2001. www.academicpress.com/cbi.

89. Huynh HT, Teel RW. Selective induction of apoptosis in human mammary cancer cells (MCF-7) by pycnogenol. Anticancer Res. 20, 4:2417-20, 2000. www.geocities.com/Athens/Rhodes/8729/iiar/iiar.htm.

90. Bouic PJ. The role of phytosterols and phytosterolins in immune modulation: a review of the past 10 years. Curr Opin Clin Nutr Metab Care. 4, 6:471-5, 2001. www.co-clinicalnutrition.com.

91. Lu H et al. A water-soluble extract from cultured medium of Ganoderma lucidum (Rei-shi) mycelia suppresses azoxymethane-induction of colon cancers in male F344 rats. Oncol Rep. 10, 2:375-9, 2003. http://virology.med.uoc.gr/OR/or.htm.

92. Hu H et al. Ganoderma lucidum extract induces cell cycle arrest and apoptosis in MCF-7 human breast cancer cell. Int J Cancer. 102, 3:250-3, 2002. www3.interscience.wiley.com.

93. Sliva D et al. Ganoderma lucidum suppresses motility of highly invasive breast and prostate cancer cells. Biochem Biophys Res Commun. 298, 4:603-12, 2002.

94. Fullerton SA et al. Induction of apoptosis in human prostatic cancer cells with beta-glucan (Maitake mushcroom polysaccharide). Mol Urol. 4, 1:7-13, 2000. www.liebertpub.com/mou/default1.asp.

95. Inoue A et al. Effects of maitake (Grifola frondosa) D-fraction on the control of the T lymph node Th-1/Th-2 proportion. Biol Pharm Bull. 25, 4:536-40, 2002.

96. Kodama N et al. A polysaccharide, extract from Grifola frondosa, induces Th-1 dominant responses in carcinoma-bearing BALB/c mice. Jpn J Pharmacol. 90, 4:357-60, 2002.

97. Kodama N et al. Effects of D-fraction, a polysaccharide from Grifola frondosa, on tumor growth involve activation of NK cells. Biol Pharm Bull. 25, 12:1647-50, 2002.

98. Kodama N et al. Can maitake MD-fraction aid cancer patients? Altern Med Rev. 7, 3:236-9, 2002. www.thorne.com/altmedrev.

99. Ohno N et al. Antitumor beta glucan from the cultured fruit body of Agaricus blazei. Biol Pharm Bull. 24, 7:820-8, 2001.

100. Oshiman K et al. Orally administered beta-1,6-D-polyglucose extracted from Agaricus blazei results in tumor regression in tumor-bearing mice. Planta Med. 68, 7:610-4, 2002.

101. Barbisan LF et al. Agaricus blazei (Himematsutake) does not alter the development of rat diethylnitrosamine-initiated hepatic preneoplastic foci. Cancer Sci. 94, 2:188-92, 2003.

102. Takaku T et al. Isolation of an antitumor compound from Agaricul blazei Murill and its mechanism of action. J Nutr. 131, 5:1409-13, 2001. www.nutrition.org.

103. Burikhanov R et al. "Suppressive effect of Active Hexose Correlated Compound (AHCC) on thymic apoptosis induced by dexamethasone in the rat." Endocrin Reg. 34:181-88, 2000.

104. Uno K et al. "Active Hexose Correlated Compound (AHCC) improves immunological parameters and performance status of patients with solid tumors." Biotherapy. 14, 3:303-9, 2000. www.kluweronline.com/issn/0921-299X/current.

105. Matsui Y et al. Improved prognosis of postoperative hepatocellular carcinoma patients when treated with functional foods: a prospective cohort study. J Hepatol. 37, 1:78-86, 2002. www.jhep-elsevier.com.

106. Kuo PL et al. The antiproliferative activity of aloe-emodin is through p53-dependent and p21-dependent apoptotic pathway in human hepatoma cell lines. Life Sci. 71, 15:1879-92, 2002. www.sciencedirect.com/science/journal/00243205.

107. Pugh N et al. Characterization of Aloeride, a new high-molecular-weight polysaccharide from Aloe vera with potent immunostimulatory activity. J Agric Food Chem. 49, 2:1030-4, 2001. http://pubs.acs.org/journals/jafcau.

108. Olsen DL et al. The effect of aloe vera/mild soap versus mild soap alone in preventing skin reactions in patients undergoing radiation therapy. Oncol Nurs Forum. 28, 3:543-7, 2001.

109. Heggie S et al. A phase III study on the efficacy of topical aloe vera gel on irradiated breast tissue. Cancer Nurs. 25, 6:442-51, 2002.

110. Rahman KM et al. Indole-3-carbinol (I3C) induces apoptosis in tumorigenic but not in nontumorigenic breast epithelial cells. Nutr Cancer. 45, 1:101-12, 2003. www.erlbaum.com/Journals/journals/NC/nc.htm.

111. Brandi G et al. A new indole-3-carbinol tetrameric derivative inhibits cyclin-dependent kinase 5 expression, and induces G1 cell cycle arrest in both estrogen-dependent and estrogen-independent breast cancer cell lines. Cancer Res. 63, 14:4028-36, 2003. http://cancerres.aacrjournals.org.

112. Auborn KJ et al. Indole-3-carbinol is a negative regulator of estrogen. J Nutr. 133, 7 Suppl:2470S-2475S, 2003. www.nutrition.org.

113. Jeon KI et al. Pretreatment of indole-3-carbinol augments TRAIL-induced apoptosis in a prostate cancer cell line, LNCaP. FEBS Lett. 544, 1-3:246-51, 2003. www.elsevier.com/febs//show.

114. Nachshon-Kedmi et al. Indole-3-carbinol and 3,3-diindolylmethane induce apoptosis in human prostate cancer cells. Food Chem Toxicol. 41, 6:745-52, 2003. www.elsevier.nl/locate/foodchemtox.

115. Frydoonfar HR et al. The effect of indole-3-carbinol and sulforaphane on a prostate cancer cell line. ANZ J Surg. 73, 3:154-6, 2003.

116. Frydoonfar HR et al. Inhibition of proliferation of a colon cancer cell line by indole-3-carbinol. Colorectal Dis. 4, 3:205-7, 2002. www.blackwellpublishing.com.

117. Scholz M et al. Modified citrus pectin (MCP) increases the prostate specific antigen doubling time in men with prostate cancer: a phase II clinical trial. The First International, Interdisciplinary Conference on The Science of Whole Person Healing, Bethesda, Md., March 28-30, 2003. www.wholepersonhealing.com.

118. Nangia-Makker et al. Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin. J Natl Cancer Inst. 94:1854-62, 2002. http://jncicancerspectrum.oupjournals.org/jnci.

119. Atalay M et al. Anti-angiogenic property of edible berry in a model of hemangioma. FEBS Lett. 544, 1-3:252-7, 2003. www.elsevier.com/febs//show.

120. Moon EJ et al. Anti-angiogenic activity of conjugated linoleic acid on basic fibroblast growth factor-induced angiogenesis. Oncol Rep. 10, 3:617-21, 2003. http://virology.med.uoc.gr/OR/or.htm.

121. Kim EJ et al. Conjugated linoleic acid downregulates insulin-like growth factor-I receptor levels in HT-29 human colon cancer cells. J Nutr. 133, 8:2675-81, 2003. www.nutrition.org.

122. Cheng JL et al. Dose response study of conjugated fatty acid derived from safflower oil on mammary and colon carcinogenesis pretreated with 7,12-dimethylbenz[a]anghracene (DMBA) and 1,2-dimethylhydrazine (DMH) in female Sprague-Dawley rats. Cancer Lett. 196, 2:161-8, 2003. www.elsevier.com/locate/canlet.

Share this article: Email, Slashdot, Digg, Del.icio.us, Yahoo!MyWeb, Windows Live Favorites, Furl
Add this article feed to: RSS, My Yahoo, Newsgator, Bloglines